Eyeworld

I MAY 2020 | EYEWORLD | 53 Stratifying products As with MIGS when many options were coming to the market, Dr. Al-Aswad said she thinks there will be a place for various modes of delivery. "I think we're going to see what survives from these, how will they work, their side effects, the compliance with them, and the com- plication rates. According to that, we will decide what will work for us," Dr. Al-Aswad said. "In addition, by having all of these options, we can tailor it to the patient's needs. … Depending on their needs and other factors, that might push us in one direction or another." Dr. Williamson envisioned a product like iDose being paired with MIGS procedures, because the surgeon would already be inside the eye. In terms of the day to day clinic, that's where he thinks products like Durysta would come into play. As with any procedure and medication, there will be risks, but Dr. Williamson said it's they could someday be used for glaucoma ther- apy as well. Ocular Therapeutix is in Phase 3 testing stages with OTX-TP, a travoprost insert designed to deliver the drug for up to 90 days. Mati Therapeutics with Evolute is in clinical trials to deliver latanoprost through an intracan- alicular insert. Similar to Durysta's delivery as an intracam- eral implant is Envisia Therapeutics' ENV515, which is in Phase 2 trials to release travoprost over an 11-month period. Ocular Therapeutix's OTX-TIC, an intracameral travoprost implant with a targeted drug duration of 4–6 months, is also under clinical evaluation, recently complet- ing its Phase 1 clinical trial. Further work is being done on a range of injectable drugs (Clearside Biomedical/Santen, IBI-60089, EyePoint Pharmaceuticals, GB-401, Graybug Vision), gel-forming drops (SoliDrop, Otero Therapeutics), intrascleral implants (Ophthalmic MicroPump System, Replenish), and latanoprost-eluting contact lenses, among the other possible sustained-release drug deliv- ery options. continued on page 54 The Durysta sustained-release implant in the anterior chamber Source: © 2020 Allergan. Used with permission. All rights reserved. About the doctors Lama Al-Aswad, MD Professor of ophthalmology Director of teleophthalmology, artificial intelligence and innovation New York University Langone Eye Center New York, New York Blake Williamson, MD Williamson Eye Center Baton Rouge, Louisiana

• Blank Page
• Blank Page (1)